The main differences from the original guidelines are that the text has been shortened with some style changes to enable the application to be user friendly, and removal of supporting text and references. There are no differences in key recommendations between the application and the published version of these guidelines. Newer data regarding use of Dolutegravir with TB therapy has been added.